InnoCare is committed to developing innovative medicines and addressing the unmet medical needs in the fields of autoimmune disease and cancer through internal research and licensing. We are actively pursuing opportunities in multiple ways.
- In-licensing of selective and potent targeted therapies in the clinical stages for autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis as well as cancers that are prevalent in China such as Hepatocellular Carcinoma (HCC) and Gastrointestinal Stromal Tumor (GIST). We believe that our insights in personalized genomic profiling will bring successes to the clinical therapy developments for these diseases.
- Collaborations in combinational therapies for immuno-oncology. Our pipeline, which covers checkpoint inhibitors, Treg suppression, and tumor-associated macrophage (TAM) modulators, offers increased opportunities for the targeted selection treatments to treat different types of solid tumors.
- Creative partnerships in the clinical development phase for our selected assets in the international market to bring our innovative scientific solutions to the bedsides of patients in China and worldwide.